GLIMITERIS TRIO 0.3 :Uses, Side Effects, Dosage and Call to action....

GLIMITERIS TRIO 0.3 

Voglibose 0.3 mg, Glimepiride 3 mg & Metformin Hydrochloride 500 mg

GLIMITERIS TRIO 0.3 is a combination medication designed to manage type 2 diabetes mellitus effectively. This medication brings together three potent antidiabetic agents: Voglibose 0.3 mg, Glimepiride 3 mg, and Metformin Hydrochloride 500 mg. By leveraging the synergistic effects of these components, GLIMITERIS TRIO 0.3 helps in maintaining optimal blood glucose levels, reducing complications associated with diabetes.

Key Ingredients
Voglibose (0.3 mg): Voglibose is an alpha-glucosidase inhibitor that delays glucose absorption from the intestines. It helps in controlling postprandial hyperglycemia, which is the rise in blood sugar levels following meals.
Glimepiride (3 mg): Glimepiride belongs to the sulfonylurea class and stimulates the release of insulin from pancreatic beta cells. This action enhances insulin secretion, thus lowering blood glucose levels.
Metformin Hydrochloride (500 mg): Metformin is a biguanide that reduces hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity. It is a cornerstone in the management of type 2 diabetes.
How Does It Work?
GLIMITERIS TRIO 0.3 works through multiple mechanisms to control blood glucose levels effectively:

Voglibose delays carbohydrate digestion and absorption, preventing spikes in blood sugar after meals.
Glimepiride increases insulin secretion, thus aiding in the immediate reduction of blood glucose levels.
Metformin reduces the amount of glucose produced by the liver and enhances the sensitivity of body tissues to insulin, facilitating better glucose uptake and utilization.
Uses
GLIMITERIS TRIO 0.3 is primarily used for:

Managing Type 2 Diabetes Mellitus: This medication is prescribed when diet, exercise, and monotherapy with a single antidiabetic agent do not provide adequate glycemic control.
Improving Glycemic Control: It helps in maintaining consistent blood sugar levels, thus reducing the risk of diabetes-related complications.
Dosage
The dosage of GLIMITERIS TRIO 0.3 should be individualized based on the patient's current treatment regimen, effectiveness, and tolerability. The general guidelines include:

Starting Dose: One tablet per day, taken with meals to enhance the effectiveness of Voglibose and Metformin and to minimize gastrointestinal side effects.
Adjustment: The dose may be adjusted by the physician based on the patient’s glycemic response and tolerance.
Side Effects
Like any medication, GLIMITERIS TRIO 0.3 may cause side effects, although not everyone experiences them. Common side effects include:

Gastrointestinal Issues: Such as nausea, vomiting, diarrhea, and abdominal pain, primarily due to Metformin and Voglibose.
Hypoglycemia: Particularly due to Glimepiride, especially when combined with other antidiabetic drugs, missed meals, or excessive physical activity.
Weight Gain: Associated with Glimepiride, though Metformin may counteract this to some extent.
Safety Information
Before starting GLIMITERIS TRIO 0.3, it is essential to consider the following safety information:

Kidney Function: Regular monitoring is required, as Metformin is contraindicated in severe renal impairment.
Liver Function: Patients with liver disease should use this medication cautiously.
Cardiovascular Risk: Although beneficial, sulfonylureas like Glimepiride may pose a risk in patients with cardiovascular diseases.
Pregnancy and Lactation: The safety of GLIMITERIS TRIO 0.3 during pregnancy and lactation has not been established. 
Conclusion
GLIMITERIS TRIO 0.3 is a comprehensive antidiabetic medication that offers a multi-faceted approach to managing type 2 diabetes mellitus. Combining Voglibose, Glimepiride, and Metformin, it effectively controls blood sugar levels and reduces the risk of diabetes-related complications. However, it is essential to use this medication under the guidance of a healthcare provider, considering individual health conditions and potential side effects. Regular monitoring and lifestyle modifications, along with GLIMITERIS TRIO 0.3, can lead to better diabetes management and an improved quality of life.Steris Healthcare Pvt Ltd, operating as Sterispharma since its founding by expert professionals in the pharmaceutical industry in February 2018, is based in Navi Mumbai. The company is certified by WHO, GMP, and ISO, emphasizing its commitment to quality and safety. Sterispharma focuses on providing high-quality drugs at affordable prices throughout India, adhering strictly to WHO guidelines. Offering the convenience of an online pharmacy, customers can easily purchase medicines with home delivery options available. Sterispharma's mission is to supply a broad range of healthcare products to meet the diverse needs of the medical community. From advanced treatments and medications for rare conditions to essential health necessities, Sterispharma aims to serve the extensive demands of the healthcare industry. You can order medicines from Sterispharma through their websites, sterisonline and sterispharma. Their extensive product lineup includes treatments for Cardiology, Asthma, Respiratory Issues, Nasal Conditions, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infectives/Antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental Care, and Dermatology. 

For further information 

Email: info@sterispharma.com / contact@sterispharma.com

Call/WhatsApp:  7877551268, 7849827488  

BUY NOW